In the Spotlight...
B cell-derived IL-27 promotes control of persistent LCMV infection
REVIEW: Tertiary lymphoid structures in cancer
Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate
HLA-independent T cell receptors for targeting tumors with low antigen density
Previous Digests
New year, new IL-12
January 19, 2022
Strategies to activate tumor-infiltrating lymphocytes (TILs) can support existing cancer therapies and overcome resistance mechanisms such as exhaustion. One such approach, the inflammatory cytokine IL-12, can activate T cells and may be linked to patient survival, but its application...
With the powers of the immunoproteasome, MSCs can become APCs
January 12, 2022
Over the years, dendritic cell (DC) vaccines have consistently shown promise, but have come up short in the clinic, potentially due to poorly presented antigens, limited in vivo persistence, or impaired function when derived autologously from patients with cancer. As...
First-in-class vaccine against IDO and PD-L1 enhances anti-PD-1 in phase I/II clinical trial
December 22, 2021
Drugs targeting the PD-1/PD-L1 axis, like nivolumab, have revolutionized treatment of patients with metastatic melanoma. However, many patients still either do not respond or develop resistance to therapy. In an effort to modulate tumor microenvironments (TMEs) to enhance responses...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
Donate to support researchersAbout ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Lespinasse-Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Samuel (Sandy) Goldman
Paula Hochman
Shishir Pant
Elaine Yee Lin Chung
Nathan Suek
Margot O'Toole
Taylor Lord
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
